Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Stockholm, Stockholm and currently employs 1,888 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Hasılat
28,237
28,238
26,027
22,123
18,790
15,529
Hasılat Artışı (YoY)
8%
9%
18%
18%
21%
2%
Satınalma Maliyeti
5,960
5,967
5,717
4,952
4,413
3,484
Brüt Kâr
22,277
22,271
20,310
17,171
14,377
12,045
Satış, Genel ve İdari
7,669
7,806
7,302
6,668
5,415
4,341
Araştırma ve Geliştirme
3,250
3,249
3,503
2,719
2,228
1,981
İşletme Giderleri
14,266
14,268
14,488
12,495
9,856
8,258
Diğer Finansman Gelirleri (Giderleri)
0
1
-59
-51
-28
-35
Kâr Öncesi Gelir
34
34
4,407
2,954
3,321
3,295
Kira Vergisi Gideri
-442
-442
528
546
683
616
Net Kâr
478
478
3,885
2,409
2,638
2,679
Net Income Growth
Kâr Artışı
-88%
-88%
61%
-9%
-2%
-17%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
348.5
348.65
345.56
325.96
312.45
310.72
Hisse Değişimi (Yıllık Üst Üste)
0%
1%
6%
4%
1%
0%
EPS (Diluted)
1.37
1.37
11.24
7.39
8.44
8.62
EPS Artışı
-88%
-88%
52%
-12%
-2%
-17%
Öz sermaye akışı
5,412
5,412
4,383
-473
3,099
5,100
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
78.89%
78.86%
78.03%
77.61%
76.51%
77.56%
Faaliyet Kâr Marjı
28.37%
28.34%
22.36%
21.13%
24.06%
24.38%
Kâr Marjı
1.69%
1.69%
14.92%
10.88%
14.03%
17.25%
Özsermaye Karlılık Oranı
19.16%
19.16%
16.84%
-2.13%
16.49%
32.84%
EBITDA
11,315
11,170
9,513
7,794
6,767
5,753
EBITDA Marjinali
40.07%
39.55%
36.55%
35.23%
36.01%
37.04%
D&A EBITDA için
3,304
3,167
3,691
3,118
2,246
1,966
Faaliyet Kârı
8,011
8,003
5,822
4,676
4,521
3,787
Faaliyet Kâr Marjı
28.37%
28.34%
22.36%
21.13%
24.06%
24.38%
Verilen Vergi Oranı
-1,300%
-1,300%
11.98%
18.48%
20.56%
18.69%
Follow-Up Questions
¿Cuáles son los estados financieros clave de Swedish Orphan Biovitrum AB (publ)?
Según el último estado financiero (Form-10K), Swedish Orphan Biovitrum AB (publ) tiene un total de activos de $67,434, una ganancia neta kâr de $478
¿Cuáles son los ratios financieros clave para BIOVF?
El ratio corriente de Swedish Orphan Biovitrum AB (publ) es 2.26, el margen neto es 1.69, las ventas por acción son $80.99.
¿Cómo se desglosan los ingresos de Swedish Orphan Biovitrum AB (publ) por segmento o geografía?
Swedish Orphan Biovitrum AB (publ) en büyük gelir kaynağı Haematology olup, en son kar bildiriminde geliri 13,370,000,000 dir. Coğrafi olarak, United States , Swedish Orphan Biovitrum AB (publ) için ana pazar olup, geliri 8,148,000,000 dir.
¿Es rentable Swedish Orphan Biovitrum AB (publ)?
evet, según los últimos estados financieros, Swedish Orphan Biovitrum AB (publ) tiene una ganancia neta kâr de $478
¿Tiene Swedish Orphan Biovitrum AB (publ) alguna deuda?
evet, Swedish Orphan Biovitrum AB (publ) tiene una deuda de 29,717
¿Cuántas acciones en circulación tiene Swedish Orphan Biovitrum AB (publ)?
Swedish Orphan Biovitrum AB (publ) tiene un total de acciones en circulación de 345.66